Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lawrence

Showing results (481-490 of 534) with videos related to

Pageof 54
Sort By:
The British Journal of Dermatology|October 12, 2018
Sunscreen applied at ≥ 2 mg cm<sup>-2</sup> during a sunny holiday prevents erythema, a biomarker of ultraviolet radiation-induced DNA damage and suppression of acquired immunityJ Narbutt, P A Philipsen, G I Harrison, et al.
Journal for Immunotherapy of Cancer|November 13, 2021
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trialPatrick A Ott, Matthew Nazzaro, Kathleen L Pfaff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2016
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory MelanomaDanny N Khalil, Michael A Postow, Nageatte Ibrahim, et al.
The Review of Scientific Instruments|October 2, 2007
Controller-area-network bus control and monitor system for a radio astronomy interferometerDavid P Woody, Bradley Wiitala, Stephen L Scott, et al.
Oncoimmunology|May 4, 2018
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanomaMeghan J Mooradian, Alexandre Reuben, Peter A Prieto, et al.
Journal for Immunotherapy of Cancer|May 16, 2025
Tumor location as a risk factor for severe immune-related adverse eventsSteven M Blum, Ben Ouyang, Leyre Zubiri, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 28, 2023
Diffusion-weighted imaging on an MRI-linear accelerator to identify adversely prognostic tumour regions in glioblastoma during chemoradiationLiam S P Lawrence, Rachel W Chan, Hanbo Chen, et al.
Journal of AOAC International|March 12, 2005
Microbiological assay-trienzyme procedure for total folates in cereals and cereal foods: collaborative studyJonathan W DeVries, Jeanne I Rader, Pamela M Keagy, et al.
The Lancet. Oncology|June 9, 2016
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trialJeffrey S Weber, Geoff Gibney, Ryan J Sullivan, et al.
Plos One|July 1, 2024
Correction: Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentAdam A Friedman, Arnaud Amzallag, Iulian Pruteanu-Malinici, et al.
Pageof 54

Showing results (481-490 of 534) with videos related to

Sort By:
Pageof 54
The British Journal of Dermatology|October 12, 2018
Sunscreen applied at ≥ 2 mg cm<sup>-2</sup> during a sunny holiday prevents erythema, a biomarker of ultraviolet radiation-induced DNA damage and suppression of acquired immunityJ Narbutt, P A Philipsen, G I Harrison, et al.
Journal for Immunotherapy of Cancer|November 13, 2021
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trialPatrick A Ott, Matthew Nazzaro, Kathleen L Pfaff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2016
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory MelanomaDanny N Khalil, Michael A Postow, Nageatte Ibrahim, et al.
The Review of Scientific Instruments|October 2, 2007
Controller-area-network bus control and monitor system for a radio astronomy interferometerDavid P Woody, Bradley Wiitala, Stephen L Scott, et al.
Oncoimmunology|May 4, 2018
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanomaMeghan J Mooradian, Alexandre Reuben, Peter A Prieto, et al.
Journal for Immunotherapy of Cancer|May 16, 2025
Tumor location as a risk factor for severe immune-related adverse eventsSteven M Blum, Ben Ouyang, Leyre Zubiri, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 28, 2023
Diffusion-weighted imaging on an MRI-linear accelerator to identify adversely prognostic tumour regions in glioblastoma during chemoradiationLiam S P Lawrence, Rachel W Chan, Hanbo Chen, et al.
Journal of AOAC International|March 12, 2005
Microbiological assay-trienzyme procedure for total folates in cereals and cereal foods: collaborative studyJonathan W DeVries, Jeanne I Rader, Pamela M Keagy, et al.
The Lancet. Oncology|June 9, 2016
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trialJeffrey S Weber, Geoff Gibney, Ryan J Sullivan, et al.
Plos One|July 1, 2024
Correction: Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentAdam A Friedman, Arnaud Amzallag, Iulian Pruteanu-Malinici, et al.
Pageof 54